Skip to main content
Patient Education Logo
Home > Events > On Demand: How AAV Vectors Are Made

Lunch & Learn: How AAV Vectors Are Made

We often hear that gene therapies are complex and require a lot of time and money to make. But what does that really mean? Tune in to hear experts in the field help answer this question by walking us through the manufacturing process.

Agenda

Thursday, April 28
12-1 p.m. (CT) 

Introduction
12 – 12:05 p.m.
Laura Hameed, Executive Director, Columbus Children’s Foundation
 

How AAV Vectors Are Made
12:05 – 12:40 p.m.
David Dismuke, PhD, Chief Technical Officer, Forge Biologics
Michelle Berg, President, GMP Nucleic Acids, Aldevron

Dr. Dismuke and Ms. Berg will provide an integrated presentation highlighting the different methods for making AAV vectors, the importance of quality control and quality assurance at the different stages of drug development, as well as the current and future state of manufacturing capacity and timelines. They will also address the criticality of advanced planning for future success from the clinical and regulatory perspective and how costly (money and time) changes can be prevented. 

Moderated Q&A 
12:40 p.m. – 1:00 p.m.  

Last Updated: 05/02/2022

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.